Clinical, immunophenotypic, and cytogenetic characteristics of high‐grade myelodysplastic syndromes with CD41‐positive progenitor cells. Issue 1 (28th December 2021)

• Record Type: Journal Article
• Authors: Ogata, Kiyoyuki; Sei, Kazuma; Kawahara, Naoya; Ogata, Mika; Yamamoto, Yumi
• Other Names: Kern Wolfgang guestEditor.; van de Loosdrecht Arjan guestEditor.
• Is Part Of: Cytometry. Volume 104:Issue 1(2023)
• Page Start: 98
• Page End: 107
• Publication Date: 2021-12-28
• Subjects: CD41 -- cytogenetics -- immunophenotypes -- myelodysplastic syndromes; Flow cytometry -- Diagnostic use -- Periodicals; Cytodiagnosis -- Periodicals; 616.07582
• DOI: 10.1002/cyto.b.22052
• Languages: English
• ISSNs: 1552-4949

Abstract

Abstract: Background: Patients with myelodysplastic syndromes (MDS) with progenitors expressing CD41 (CD41+ MDS) showed a poor prognosis in a previous study but their detailed characteristics remain unclear. Methods: One hundred thirty‐seven subjects at our institution were diagnosed with excess blasts (EB)‐1, EB‐2, and acute myeloid leukemia with a low blast count (20%–30%). The immunophenotypes of progenitor cells in their bone marrow (BM) were determined by CD45‐gating flow cytometry. A false‐positive reaction to CD41 was eliminated by examining the flow cytometry data of lymphocytes and monocytes in addition to progenitors and by examining CD42b in histological sections. The characteristics were compared between CD41+ and CD41− MDS patients. Results: Forty‐three patients (31%) were CD41+. Additionally, 91% of the CD41+ MDS patients were very high‐risk defined by the Revised International Prognostic Score System, which was higher than in patients with CD41− MDS ( p = 0.015). Approximately 60% of the CD41+ MDS patients had a monosomal karyotype and very poor cytogenetics, which was higher than in CD41− MDS patients ( p < 0.001). Normal cytogenetics was less common in CD41+ patients ( p = 0.0016). Blasts with bleb formation were more abundant in CD41+ MDS patients ( p = 0.026). All CD41+ MDS patients were positive for CD13 and were mostly positive for CD33. The frequency of aberrant expression of other antigens on progenitors was similar between CD41+ and CD41− MDS patients. Conclusions: We determined clinical, immunophenotypic, and cytogenetic characteristics of CD41+ MDS patients. Further studies are needed to improve the survival of these patients.